Join the Oncology Voice Network. Join for Free
The MSL Secret Weapon for Insightful Engagement
MSL secret weapon insightful engagement curiosity mindset KOL interactions powerful questions

The MSL Secret Weapon for Insightful Engagement


Share This Article


Summary

In this week’s episode, Mary Winkels, Global Director, Medical Affairs Training and Capability at Vertex Pharmaceuticals discusses the MSL secret weapon for insightful engagement.

Learn more about…

👉 What is the MSL “secret weapon” for insightful engagement
👉 How MSLs can build the curiosity and question asking muscle
👉 The skill gap for most MSLs in KOL interactions
👉 The art of asking powerful questions
👉 The value created by developing a curiosity mindset

Click for Source
MSL secret weapon, insightful engagement, curiosity mindset, KOL interactions, powerful questions

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The Power of Non Traditional KOL Engagement
Partner Avatar MSL Talk: Tom Caravela, Lindsey Harrer

The Power of Non Traditional KOL Engagement

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Explore OVN